Study of CXCR4-targeted 68Ga-pentixafor PETCT Compared to 18F-FDG PETCT for Diagnosing and Staging Hematological Malignancies

What this Trial Is About

Hematological malignancies are a diverse group of cancers affecting the bone marrow and lymphatic system, often challenging to diagnose and treat due to their varied nature and high mortality. Researchers are evaluating a new imaging method called 68Ga-pentixafor PETCT, which targets the CXCR4 receptor commonly overexpressed in these cancers. This study aims to compare this method with the standard 18F-FDG PETCT to improve diagnosis, staging, risk assessment, and prognosis prediction in affected patients. Participants will receive both 68Ga-pentixafor and 18F-FDG PETCT scans within two weeks. The 68Ga-pentixafor is given intravenously at a dose based on body weight, and imaging is performed one hour after injection. The study also uses artificial intelligence to analyze images, helping detect lesions, measure tumor characteristics, and support personalized treatment decisions. This approach will be explored alongside standard imaging to enhance disease evaluation. During the study, patients will follow scheduled visits, treatments, and laboratory tests. Researchers will assess diagnostic accuracy, staging agreement with clinical systems, and the ability of 68Ga-pentixafor PETCT to predict progression-free and overall survival over several years. The study includes safety monitoring and aims to develop AI models for risk prediction. Participation may last up to four years with ongoing evaluations to support personalized care.

CXCR4-targeted PET/CT Imaging in Hematological Malignancies